BAO PHARMA-B (02659) has announced that its self-developed recombinant human chymotrypsin KJ101, a leading product in China developed through synthetic biology, has received approval from China's National Medical Products Administration to commence clinical trials in China for dissolving and removing gastric mucus during gastroscopy procedures. Chymotrypsin is a protease capable of rapidly decomposing proteins and liquefying pus and necrotic tissue. Due to its specific proteolytic activity, it can effectively break down fibrin, collagen fragments, and other protein debris that accumulate in chronic or acute wounds. Chymotrypsin is widely used in departments such as respiratory medicine, surgery, otolaryngology, obstetrics and gynecology, pediatrics, dentistry, ophthalmology, dermatology, gastroenterology, and proctology, particularly for removing necrotic tissue, promoting wound healing, and improving visual field during gastroscopy. KJ101 is a leading recombinant human chymotrypsin in China developed through the company's synthetic biology platform, designed to fully replace animal-derived products. Based on the company's unique recombinant yeast fermentation technology, KJ101 offers a purer, safer, and more scalable alternative with high expression levels. KJ101 boasts core advantages including high purity, no risk of animal-derived virus contamination, and non-allergenic properties. Its raw materials are widely sourced, with supply unaffected by fluctuations in the upstream livestock farming industry. The product exhibits minimal batch-to-batch variation and is not impacted by changes in raw material quality, ensuring excellent clinical safety. For wound healing indications such as burns, trauma, surgical incisions, pressure ulcers, and diabetic foot ulcers, the company received IND approval for KJ101 from the National Medical Products Administration in February 2025 and initiated its Phase II clinical trial in July 2025.